ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: On the other hand, because imatinib does not have a significant effect on CML stem cells, we would not expect that imatinib stimulates the transition of BCR-ABL-expressing LSK cells to LSK− cells.